November 2, 2021, Vol 326, No. 17, Pages 1655-1756
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19The ACTIV-4B Randomized Clinical Trial
Jean M. Connors, MD; Maria M. Brooks, PhD; Frank C. Sciurba, MD; et al.
JAMA. 2021;326(17):1703-1712. doi:10.1001/jama.2021.17272
This randomized clinical trial assesses whether aspirin, prophylactic-dose apixaban, or therapeutic-dose apixaban, compared with placebo, can safely reduce major adverse cardiopulmonary outcomes among symptomatic but clinically stable US outpatients with COVID-19.